

CASE TX/4-32608A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV97183292515
Express Mail Label Number

NOVEMBER 14, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1636

KRAUSE ET AL.

Examiner: Schlapkohl, Walter

APPLICATION NO: 10/524,399

FILED: FEBRUARY 11, 2005

FOR: DIAGNOSIS OF CHRONIC REJECTION

1 **MS: Amendment**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This communication is in response to the Office Action of May 17, 2007. In the Action, the Examiner imposed a restriction requirement between:

Claim Group I, claim(s) 1-3, 6 and 8-11, drawn to a method of early diagnosis/monitoring of chronic rejection (CR) comprising comparing a baseline level of a gene's expression to the same gene's expression level in an allograft tissue biopsy of the same tissue type within the first year post-transplantation.

Claim Group II, claim(s) 4, drawn to a method comprising the step of administering a compound that modulates expression of one or more genes.


Claim Group III, claim(s) 5 and 8, drawn to a method of identifying agents for use in prevention, inhibition, reduction or treatment of CR comprising the use of one or one combination of genes selected from those listed in claim 7.

Accordingly, Applicants elect the subject matter of Claim Group I for further prosecution in this application.

An early favorable action on the merits is respectfully requested.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-9308

Respectfully submitted,



Leslie Fischer
Attorney for Applicants
Reg. No. 58,393

Date: 11/14/07